Treatment and survival in diffuse malignant pleural mesothelioma; a study of 83 cases from the Massachusetts General Hospital

Michael Huncharek, Karl Kelsey, Eugene J. Mark, Joshua Muscat, Noah Choi, Robert Carey, David Christiani

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The influence of treatment on clinical outcome in pleural mesothelioma (PM) is uncertain. We studied 83 patients with PM treated at our institution to evaluate the impact of treatment modality on survival. Methods. Medical records of 83 patients with PM treated between 1978 and 1994 were reviewed. The following data were tabulated for each patient; age, sex, date of diagnosis, history of asbestos exposure, smoking history, method of diagnosis, histologic subtype, type of treatment and survival from diagnosis. Four treatment groups were analyzed; chemotherapy (C), surgery (S), combined modality (CM i.e. S+C with or without radiation therapy) and supportive care alone (SC). Survival curves were calculated and adjustment made for age. Survival curves were compared using Wilcoxon Chi-square analysis. Results. Seventy-one males and 12 females with a mean of 67 years were analyzed. Seventy-five percent were smokers and 74% reported definite or probable asbestos exposure. Treatment groups did not vary according to smoking or asbestos history. The CM group and SC groups contained similar proportions of patients with epithelial tumors (54% v 56%). Median survival for patients in the CM group was 23.9 months versus 4.5 months among those receiving SC (p < 0.01). Discussion. This analysis suggest prolonged survival among patients with PM receiving CM versus SC or single modality treatments.

Original languageEnglish (US)
Pages (from-to)1265-1268
Number of pages4
JournalAnticancer Research
Volume16
Issue number3 A
StatePublished - May 1 1996

Fingerprint

General Hospitals
Mesothelioma
Survival
Asbestos
Therapeutics
Smoking
History
Social Adjustment
Medical Records
Malignant Mesothelioma
Radiotherapy
Drug Therapy
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Huncharek, M., Kelsey, K., Mark, E. J., Muscat, J., Choi, N., Carey, R., & Christiani, D. (1996). Treatment and survival in diffuse malignant pleural mesothelioma; a study of 83 cases from the Massachusetts General Hospital. Anticancer Research, 16(3 A), 1265-1268.
Huncharek, Michael ; Kelsey, Karl ; Mark, Eugene J. ; Muscat, Joshua ; Choi, Noah ; Carey, Robert ; Christiani, David. / Treatment and survival in diffuse malignant pleural mesothelioma; a study of 83 cases from the Massachusetts General Hospital. In: Anticancer Research. 1996 ; Vol. 16, No. 3 A. pp. 1265-1268.
@article{0356b9bed08644c1a2413ebde5f7db37,
title = "Treatment and survival in diffuse malignant pleural mesothelioma; a study of 83 cases from the Massachusetts General Hospital",
abstract = "The influence of treatment on clinical outcome in pleural mesothelioma (PM) is uncertain. We studied 83 patients with PM treated at our institution to evaluate the impact of treatment modality on survival. Methods. Medical records of 83 patients with PM treated between 1978 and 1994 were reviewed. The following data were tabulated for each patient; age, sex, date of diagnosis, history of asbestos exposure, smoking history, method of diagnosis, histologic subtype, type of treatment and survival from diagnosis. Four treatment groups were analyzed; chemotherapy (C), surgery (S), combined modality (CM i.e. S+C with or without radiation therapy) and supportive care alone (SC). Survival curves were calculated and adjustment made for age. Survival curves were compared using Wilcoxon Chi-square analysis. Results. Seventy-one males and 12 females with a mean of 67 years were analyzed. Seventy-five percent were smokers and 74{\%} reported definite or probable asbestos exposure. Treatment groups did not vary according to smoking or asbestos history. The CM group and SC groups contained similar proportions of patients with epithelial tumors (54{\%} v 56{\%}). Median survival for patients in the CM group was 23.9 months versus 4.5 months among those receiving SC (p < 0.01). Discussion. This analysis suggest prolonged survival among patients with PM receiving CM versus SC or single modality treatments.",
author = "Michael Huncharek and Karl Kelsey and Mark, {Eugene J.} and Joshua Muscat and Noah Choi and Robert Carey and David Christiani",
year = "1996",
month = "5",
day = "1",
language = "English (US)",
volume = "16",
pages = "1265--1268",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3 A",

}

Huncharek, M, Kelsey, K, Mark, EJ, Muscat, J, Choi, N, Carey, R & Christiani, D 1996, 'Treatment and survival in diffuse malignant pleural mesothelioma; a study of 83 cases from the Massachusetts General Hospital', Anticancer Research, vol. 16, no. 3 A, pp. 1265-1268.

Treatment and survival in diffuse malignant pleural mesothelioma; a study of 83 cases from the Massachusetts General Hospital. / Huncharek, Michael; Kelsey, Karl; Mark, Eugene J.; Muscat, Joshua; Choi, Noah; Carey, Robert; Christiani, David.

In: Anticancer Research, Vol. 16, No. 3 A, 01.05.1996, p. 1265-1268.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment and survival in diffuse malignant pleural mesothelioma; a study of 83 cases from the Massachusetts General Hospital

AU - Huncharek, Michael

AU - Kelsey, Karl

AU - Mark, Eugene J.

AU - Muscat, Joshua

AU - Choi, Noah

AU - Carey, Robert

AU - Christiani, David

PY - 1996/5/1

Y1 - 1996/5/1

N2 - The influence of treatment on clinical outcome in pleural mesothelioma (PM) is uncertain. We studied 83 patients with PM treated at our institution to evaluate the impact of treatment modality on survival. Methods. Medical records of 83 patients with PM treated between 1978 and 1994 were reviewed. The following data were tabulated for each patient; age, sex, date of diagnosis, history of asbestos exposure, smoking history, method of diagnosis, histologic subtype, type of treatment and survival from diagnosis. Four treatment groups were analyzed; chemotherapy (C), surgery (S), combined modality (CM i.e. S+C with or without radiation therapy) and supportive care alone (SC). Survival curves were calculated and adjustment made for age. Survival curves were compared using Wilcoxon Chi-square analysis. Results. Seventy-one males and 12 females with a mean of 67 years were analyzed. Seventy-five percent were smokers and 74% reported definite or probable asbestos exposure. Treatment groups did not vary according to smoking or asbestos history. The CM group and SC groups contained similar proportions of patients with epithelial tumors (54% v 56%). Median survival for patients in the CM group was 23.9 months versus 4.5 months among those receiving SC (p < 0.01). Discussion. This analysis suggest prolonged survival among patients with PM receiving CM versus SC or single modality treatments.

AB - The influence of treatment on clinical outcome in pleural mesothelioma (PM) is uncertain. We studied 83 patients with PM treated at our institution to evaluate the impact of treatment modality on survival. Methods. Medical records of 83 patients with PM treated between 1978 and 1994 were reviewed. The following data were tabulated for each patient; age, sex, date of diagnosis, history of asbestos exposure, smoking history, method of diagnosis, histologic subtype, type of treatment and survival from diagnosis. Four treatment groups were analyzed; chemotherapy (C), surgery (S), combined modality (CM i.e. S+C with or without radiation therapy) and supportive care alone (SC). Survival curves were calculated and adjustment made for age. Survival curves were compared using Wilcoxon Chi-square analysis. Results. Seventy-one males and 12 females with a mean of 67 years were analyzed. Seventy-five percent were smokers and 74% reported definite or probable asbestos exposure. Treatment groups did not vary according to smoking or asbestos history. The CM group and SC groups contained similar proportions of patients with epithelial tumors (54% v 56%). Median survival for patients in the CM group was 23.9 months versus 4.5 months among those receiving SC (p < 0.01). Discussion. This analysis suggest prolonged survival among patients with PM receiving CM versus SC or single modality treatments.

UR - http://www.scopus.com/inward/record.url?scp=0029975748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029975748&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 1265

EP - 1268

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3 A

ER -